Policy Updates on Access to and Affordability of Innovative Medicines in China

Abstract

In China, efforts to qualify innovative medical products for reimbursement used to be subject to substantial delays after regulatory approval due to fiscal and bureaucratic barriers. In this review, we surveyed the Chinese government’s most recent initiatives to improve access to innovative medicines from both the regulatory and the reimbursement aspects, which not only accelerated the launching of drugs in the Chinese market but also expanded the reimbursement coverage of such products. We also provided a discussion of the current challenges.

Areas Covered

We provided a comprehensive review of the updates in China’s national reimbursement listing policies of medicines.

Authors

Yawen Jiang Xiaoning He Gordon G. Liu Jing Wu

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×